Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID‐19 diabetic patients: A population‐based study in Lombardy
Diabetes, Obesity and Metabolism — Ojeda-Fernández L, Foresta A, Macaluso G, et al. | January 12, 2022
Researchers examined if and how metformin use modulates COVID-19 outcomes in a cohort of 31,966 patients with diabetes in Lombardy.
From a COVID-19 linkable administrative regional database, researchers retrieved data of diabetic patients over 40 years old, who had at least two prescriptions of antidiabetic drugs in 2019 and a positive test for SARS-CoV-2 between February 15, 2020 and March 15, 2021.
There appeared a correlation between metformin use and a significantly lower risk of total mortality, in-hospital mortality, hospitalization for COVID-19 and ICU admission when compared with metformin non-users.
Overall findings suggest metformin use as protective against severe COVID-19 disease, although there is a necessity for randomized clinical trials to confirm this.